New Risk • Jul 13
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Italian stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.1% average weekly change). Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Duyuru • Jun 04
Getinge Launches Vasoview Hemopro 3 Endoscopic Vessel Harvesting System Getinge announced the launch of the Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) System, including the Hemopro 3 Harvesting Tool and dedicated Hemopro 3 Power Supply. The system represents the latest evolution of Getinge's EVH platform, enhancing decades of experience supporting coronary artery bypass grafting (CABG) procedures. Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision-related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results. Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user-driven way, ensuring solutions evolve alongside clinical practice. The Vasoview Hemopro 3 system incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game-controller-style handle and a soft-touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure. The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one-click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut-and-cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH. Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rollout availability of Vasoview Hemopro 3. Recent Insider Transactions • May 31
CEO, President & Director recently bought €436k worth of stock On the 29th of May, Mattias Perjos bought around 25k shares on-market at roughly €17.43 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Mattias has been a buyer over the last 12 months, purchasing a net total of €715k worth in shares. Valuation Update With 7 Day Price Move • May 22
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €18.75, the stock trades at a forward P/E ratio of 18x. Average forward P/E is 19x in the Medical Equipment industry in Italy. Total returns to shareholders of 8.3% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €32.79 per share. New Risk • May 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.2% average weekly change). Duyuru • Apr 10
Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited. Getinge AB (publ) (OM:GETI B) acquired Pennamed Limited on April 8, 2026. The acquisition strengthens Getinge’s offering to endoscopy units across the United Kingdom (UK) by combining Pennamed’s established consumables portfolio and strong customer relationships with Getinge’s expertise in endoscope reprocessing, infection control, and washer-disinfector technology.
Getinge and Pennamed has combined 350 employees.
Abi Godfrey, Alex Parry and Matt Harvey of Grant Thornton UK LLP acted as accountants for Pennamed Limited. Emma Orriss and Nigel Beckwith of Gosschalks LLP acted as legal advisors for Pennamed Limited. Covington & Burling Llp acted as legal advisor and Ernst & Young AB acted as accountant for Getinge AB.
Getinge AB (publ) (OM:GETI B) completed the acquisition of Pennamed Limited on April 8, 2026. Duyuru • Mar 12
Getinge AB (publ) Announces Malin Persson Declines Re-Election as Board Member, Effective April 21, 2026 Getinge AB (publ) at its Annual General Meeting to be held on April 21, 2026, announced Malin Persson has declined re-election as board member. Declared Dividend • Feb 24
Dividend of kr4.75 announced Shareholders will receive a dividend of kr4.75. Ex-date: 22nd April 2026 Payment date: 28th April 2026 Dividend yield will be 25%, which is higher than the industry average of 1.7%. Sustainability & Growth Dividend is covered by both earnings (57% earnings payout ratio) and cash flows (49% cash payout ratio). The dividend has increased by an average of 5.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 47% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Board Change • Feb 24
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Jan 28
Getinge AB (publ), Annual General Meeting, Apr 21, 2026 Getinge AB (publ), Annual General Meeting, Apr 21, 2026. Duyuru • Jan 27
Getinge AB (Publ) Proposes Dividend Getinge AB (publ) announced the proposal of dividend per share of SEK 4.75 (4.60). Duyuru • Dec 19
Getinge AB Announces Malin Persson Declines Re-Election to the Board Getinge AB announced that Malin Persson, a board member since 2014, has announced that she will not be available for re-election to the board in 2026. Board Change • Dec 11
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 19
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 7 highly experienced directors. Director Ulrika Dellby was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Duyuru • Oct 21
Getinge AB (Publ) Reaffirms Earnings Guidance for the Year 2025 Getinge AB (publ) reaffirmed earnings guidance for the year 2025. The company remain with expectation for organic net sales growth to be in the range of 2% to 5% and long-term financial target of over 12% EPS growth is also intact despite the headwind from tariffs and currency. Reported Earnings • Jul 21
Second quarter 2025 earnings released: EPS: kr1.92 (vs kr1.88 in 2Q 2024) Second quarter 2025 results: EPS: kr1.92 (up from kr1.88 in 2Q 2024). Revenue: kr8.24b (flat on 2Q 2024). Net income: kr524.0m (up 2.1% from 2Q 2024). Profit margin: 6.4% (up from 6.2% in 2Q 2024). Revenue is forecast to grow 4.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Italy. Duyuru • Jul 02
Getinge AB (publ)(OM:GETI B) dropped from OMX Stockholm 30 Index Getinge AB (publ) has been dropped from the OMX OMX Stockholm 30 Index Duyuru • Mar 18
Getinge Introduces Neural Pressure Support for the Servo-U Ventilator System Getinge announces the launch of its latest innovation in ICU ventilation – Neural Pressure Support (NPS) – available for both invasive and non-invasive ventilation. Building on its most personalized ventilation modes, NAVA and NIV NAVA, these two new NPS modes offer clinicians more options to provide personalized ventilation that aims to protect both the lungs and diaphragm. For years, Getinge has been market-driving when it comes to developing first-of-its-kind intensive care ventilation modes. The medtech company is introducing NPS and NIV NPS to widen its neurally controlled ventilation offering. The new Neural Pressure Support modes give clinicians the opportunity to deliver classical pressure support ventilation, enhanced with neural trigger and breath termination in synchrony with diaphragmatic muscle activity. This may be particularly beneficial for complex and challenging ICU patient groups, such as obstructive COPD patients requiring instant synchronization and fast pressurization, and restrictive ARDS patients with stiff lungs and an excessive respiratory drive. Duyuru • Jan 29
Getinge AB (publ), Annual General Meeting, Apr 22, 2025 Getinge AB (publ), Annual General Meeting, Apr 22, 2025. Location: halmstad Sweden Duyuru • Dec 10
Getinge AB (publ) to Report Q1, 2025 Results on Apr 22, 2025 Getinge AB (publ) announced that they will report Q1, 2025 results on Apr 22, 2025